CG Oncology says its bladder cancer immunotherapy reduced the risk of tumor recurrence by 68%, results that may change how physicians treat certain patients, STAT reports.
STATBladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrenceCG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.
Which further results would you want to see before this changes standard care?